With a short percentage of shares outstanding of 3.21%, Zoetis Inc. (NYSE:ZTS) is among the 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.
On May 27, Argus downgraded Zoetis Inc. (NYSE:ZTS) from Buy to Hold following a sharp decline in the company’s share price. The research firm pointed to a steep 22% single-day drop in the stock, followed by additional weakness, as evidence of growing investor concerns about the company’s near-term growth trajectory. According to the analyst, the market reaction reflected diminishing confidence in Zoetis’ ability to sustain the level of expansion investors had previously expected, prompting a more cautious stance on the shares despite the company’s established position in the animal health industry.
Earlier, on May 22, Stifel lowered its price target on Zoetis Inc. (NYSE:ZTS) to $95 from $105 while maintaining a Hold rating. The firm acknowledged that the company’s updated 2026 guidance indicates business conditions could gradually improve over time, signaling management’s expectation for a recovery in operating performance as the year progresses. However, Stifel also noted that competitive pressures are likely to remain elevated across several key markets in the near term, creating challenges that could weigh on growth. Even so, the revised outlook suggests the company sees opportunities to strengthen its performance despite an increasingly competitive environment.
Zoetis Inc. (NYSE:ZTS) is an animal health company headquartered in Parsippany, New Jersey, and was founded in 1952. Originally established as a division of Pfizer before becoming an independent public company in 2013, Zoetis develops and commercializes a broad portfolio of medicines, vaccines, diagnostics, and genetic testing solutions for livestock and companion animals. The company plays a significant role in the pet care market by providing veterinarians and pet owners with innovative treatments, preventive products, and diagnostic tools designed to improve animal health and well-being.
While we acknowledge the risk and potential of ZTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZTS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Most Overvalued Quantum Computing Stocks According to Short Sellers and 7 Best Longevity and Anti-Aging Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center